Business Context and Reporting Period
Company: Capstone Therapeutics Corp. (formerly OrthoLogic Corp.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: Capstone is a development-stage biotechnology company with no revenue-generating operations. It focuses on two peptide-based product platforms: AZX100 (for dermal scarring and pulmonary fibrosis) and Chrysalin (for tissue repair and vascular dysfunction). The company sold its former bone device business in 2003 and has incurred cumulative net losses of approximately $137 million since becoming a development-stage entity in 2004.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $10.9 million | $13.1 million |
| Operating Expenses | $11.4 million | $14.9 million |
| Research & Development | $8.2 million | $12.0 million |
| General & Administrative | $3.2 million | $2.9 million |
| Cash and Cash Equivalents | $24.4 million | $12.9 million |
| Total Assets | $25.3 million | $37.1 million |
| Working Capital | $23.2 million | $34.4 million |
| Stockholders' Equity | $7.9 million | $34.7 million |
Note: The company reported no debt. The decrease in stockholders' equity in 2010 was primarily due to the reclassification of $15.6 million to "Potentially Redeemable Equity" related to shareholder put rights.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by $2.2 million (17%) compared to 2009. This was driven primarily by a $3.8 million reduction in R&D expenses due to decreased AZX100 clinical trial activity and the completion of Chrysalin partnering research in 2009.
- Interest Income Decline: Interest and other income dropped from $737,000 in 2009 to $356,000 in 2010 due to lower interest rates and reduced investment balances.
- Balance Sheet Shift: While cash increased by $11.5 million, total assets decreased by $11.8 million. This was largely due to the liquidation of short-term investments (which were $22.3 million in 2009 and $0 in 2010) and the reclassification of equity to potentially redeemable equity.
- Tax Benefit: The company recorded a $181,000 income tax benefit in 2010 (vs. $1.0 million in 2009) resulting from Arizona state tax legislation.
Outlook, Risks, and Contingencies
Guidance and Outlook
Management anticipates that current cash reserves ($24.4 million) are sufficient to meet projected requirements for the next year, subject to the exercise of shareholder put rights. The company plans to complete the analysis of its Phase 2 dermal scarring trial in early 2011. It is actively seeking partnering or licensing opportunities for both AZX100 and Chrysalin, as it does not have the capital to independently complete all necessary clinical trials for FDA approval.
Material Risks and Contingencies
- Shareholder Put Rights: Stockholders approved a "put right" allowing them to require the company to purchase their shares for cash at a formula-based price (approx. 90% of available cash) on or about July 31, 2011. The company estimates a potential redemption obligation of $15.6 million. Management warns that if the pending litigation (see below) results in significant damages, the put price could be zero, or the company may be unable to fund the repurchases, potentially impairing its ability to continue as a going concern.
- Qui Tam Litigation: The company is a defendant in a Federal False Claims Act lawsuit regarding its former bone device business (sold in 2003). The plaintiff seeks treble damages and penalties that could exceed the company's financial resources. The court denied the company's motion to dismiss in December 2010, and discovery has commenced. An unfavorable outcome could force liquidation.
- Nasdaq Listing Compliance: The company failed to meet the $1.00 minimum bid price requirement for the Nasdaq Capital Market. It was granted an extension until May 2, 2011, to regain compliance. Failure to do so could result in delisting.
- Going Concern: The auditor's report includes an emphasis of matter regarding the uncertainty of the put rights and litigation, raising substantial doubt about the company's ability to continue as a going concern.
Investor Verification Checklist
- Put Right Valuation: Verify the formula and assumptions used by the Board to calculate the put price, specifically how the contingent liability of the qui tam lawsuit is valued.
- Litigation Status: Monitor the discovery phase of the qui tam lawsuit for any updates on potential damages or settlement discussions.
- Nasdaq Compliance: Confirm whether the stock price sustained the $1.00 minimum bid price for the required 10 consecutive days prior to the May 2, 2011 deadline.
- Cash Burn Rate: Assess if the $24.4 million cash balance is sufficient to fund operations through 2011 without triggering the put rights or requiring dilutive financing.
- Clinical Trial Results: Review the upcoming results of the Phase 2 dermal scarring trial (expected Q1 2011) to evaluate the commercial viability of AZX100.